Current approaches to developing a preventative HIV vaccine

Current Opinion in Investigational Drugs

Volumn 6, Issue 2, 2005, Pages 155-162

  Tonini, Tiziana ^a   Barnett, Susan ^b   Donnelly, John ^b   Rappuoli, Rino ^a,b  

^a CHIRON VACCINES   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cell mediated immunity; Cytotoxic T lymphocytes; Glycoprotein; HIV 1; Humoral immunity; T cells

Indexed keywords

CD28 ANTIGEN; CYTOKINE; EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 16; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 15E; MONOCLONAL ANTIBODY 17B; MONOCLONAL ANTIBODY 19B; MONOCLONAL ANTIBODY 2182; MONOCLONAL ANTIBODY 246 D; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 447; MONOCLONAL ANTIBODY 48D; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY 559; MONOCLONAL ANTIBODY 697D; MONOCLONAL ANTIBODY CLONE 3; MONOCLONAL ANTIBODY Z13; PROTEIN IMMUNOGLOBULIN G 1B12; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG RESEARCH; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; NONHUMAN; REVIEW; VACCINATION; HUMAN; IMMUNOLOGY; T LYMPHOCYTE;

AIDS VACCINES; B-LYMPHOCYTES; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES;

EID: 15744393460     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Mukherjee JS, Farmer PE, Niyizonkiza D, McCorkle L, Vanderwarker C, Teixeira P, Kim JY: Tackling HIV in resource poor countries. Br Med J (2003) 327(7423):1104-1106.
2. Robbins JB, Schneerson R, Szu SC: Perspective: Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 171(6):1387-1398. This paper and reference [3•] describe the protective efficacy of anti-V3 domain antibody in vivo.
3. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg W, Murthy KK: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 355(6362):728-730.
4. Gauduin MC, Safrit JT, Weir R, Fung MS, Koup RA: Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J Infect Dis (1995) 171(5):1203-1209.
5. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 5(2):204-210.
6. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 6(2):207-210.
7. 1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 6(2):200-206.
8. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 75(17):8340-8347.
9. Buckner C, Gines LG, Saunders CJ, Vojtech L, Srivastava I, Gettie A, Bohm R, Blanchard J, Barnett SW, Safrit JT, Stamatotos L: Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology (2004) 320(1):167-180.
10. Haigwood NL, Watson A, Sutton WF, McClure J, Lewis A, Ranchalis J, Travis B, Voss G, Letvin NL, Hu SL, Hirsch VM, Johnson PR: Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile. Immunol Lett (1996) 51(1-2):107-114.
11. Weber J, Fenyo EM, Beddows S, Kaleebu P, Bjorndal A: Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol (1996) 70(11):7827-7832.
12. Nyambi PN, Nkengasong J, Lewi P, Andries K, Janssens W, Fransen K, Heyndrickx L, Piot P, van der Groen G: Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol (1996) 70(9):6235-6243.
13. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol (1996) 70(1):427-444.
14. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE et al: Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses (1996) 12(14):1319-1328.
15. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF 3rd, Burton DR, Ho DD, Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 69(11):6609-6617.
16. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S: Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol (2002) 76(18):9035-9045.
17. Moore JP, Trkola A, Korber B, Boots LJ, Kessler JA 2nd, McCutchan FE, Mascola J, Ho DD, Robinson J, Conley AJ: A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol (1995) 69(1):122-130.
18. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 78(23):13232-13252.
19. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber R: Diversity considerations in HIV-1 vaccine selection. Science (2002) 296(5577):2354-2360.
20. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 393(6686):705-711.
21. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 393(6686):648-659.
22. Dimmock NJ: Neutralization of animal viruses. Curr Top Microbiol Immunol (1993) 183:1-149.
23. Burton DR: Antibodies, viruses and vaccines. Nat Rev Immunol (2002) 2(9):706-713.
24. Hansen JE, Clausen H, Nielsen C, Teglbjaerg LS, Hansen LL, Nielsen CM, Dabelsteen E, Mathiesen L, Hakomori SI, Nielsen JO: Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: Peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. J Virol (1990) 64(6):2833-2840.
25. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1 → 2 mannose residues on the outer face of gp120. J Virol (2002) 76(14):7306-7321.
26. Hioe CE, Bastiani L, Hildreth JE, Zolla-Pazner S: Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. AIDS Res Hum Retroviruses (1998) 14(Suppl 3):S247-S254.
27. Ugolini S, Mondor I, Parren PW, Burton DR, Tilley SA, Klasse PJ, Sattentau QJ: Inhibition of virus attachment to CD4+ target cells is a major mechanism of T-cell line-adapted HIV-1 neutralization. J Exp Med (1997) 186(8):1287-1298.
28. Zolla-Pazner S: Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol (2004) 4(3):199-210.
29. Chan DC, Kim PS: HIV entry and its inhibition. Cell (1998) 93(5):681-684.
30. Gorny MK, Zolla-Pazner S: Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol (2000) 74(13):6186-6192.
31. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR: Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 77(10):5678-5684.
32. Tyler DS, Stanley SD, Zolla-Pazner S, Gorny MK, Shadduck PP, Langlois AJ, Matthews TJ, Bolognesi DP, Palker TJ, Weinhold KJ: Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 145(10):3276-3282.
33. Koup RA, Robinson JE, Nguyen QV, Pikora CA, Blais B, Roskey A, Panicali D, Sullivan JL: Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS (1991) 5(11):1309-1314.
34. Nag P, Kim J, Sapiega V, Landay AL, Bremer JW, Mestecky J, Reichelderfer P, Kovacs A, Cohn J, Weiser B, Baum LL: Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis (2004) 190(11):1970-1978.
35. Check E: AIDS vaccines: Back to 'plan A'. Nature (2003) 423(6943):912-914.
36. Dowbenko D, Nakamura G, Fennie C, Shimasaki C, Riddle L, Harris R, Gregory T, Lasky L: Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J Virol (1988) 62(12):4703-4711.
37. Goudsmit J: Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. AIDS (1988) 2(Suppl 1):S41-S45.
38. Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyo EM, Wahren B, Broliden K: Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA (1992) 89(2):461-465.
39. Scala G, Chen X, Liu W, Telles JN, Cohen OJ, Vaccarezza M, Igarashi T, Fauci AS: Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J Immunol (1999) 162(10):6155-6161.
40. Fung MS, Sun CR, Gordon WL, Liou RS, Chang TW, Sun WN, Daar ES, Ho DD: Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol (1992) 66(2):848-856.
41. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA (1989) 86(17):6768-6772.
42. Putney SD, Matthews TJ, Robey WG, Lynn DL, Robert-Guroff M, Mueller WT, Langlois AJ, Ghrayeb J, Petteway SR Jr, Weinhold KJ: HTLV-III/LAV-neutralizing antibodies to an E coli-produced fragment of the virus envelope. Science (1986) 234(4782):1392-1395.
43. Gorny MK, Xu JY, Gianakakos V, Karwowska S, Williams C, Sheppard HW, Hanson CV, Zolla-Pazner S: Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA (1991) 88(8):3238-3242.
44. Robinson HL: New hope for an AIDS vaccine. Nat Rev Immunol (2002) 2(4):239-250.
45. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S: Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol (1991) 65(9):4832-4838.
46. Binley JM, Ditzel HJ, Barbas CF 3rd, Sullivan N, Sodroski J, Parren PW, Burton DR: Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses (1996) 12(10):911-924.
47. Karwowska S, Gorny MK, Buchbinder A, Gianakakos V, Williams C, Fuerst T, Zolla-Pazner S: Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 8(6):1099-1106.
48. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272(5263):872-877.
49. Alkhatib G, Berger EA, Murphy PM, Pease JE: Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions. J Biol Chem (1997) 272(33):20420-20426.
50. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE: Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses (2002) 18(16):1207-1217.
51. Barnett SW, Rajasekar S, Legg H, Doe B, Fuller DH, Haynes JR, Walker CM, Steimer KS: Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine (1997) 15(8):869-873.
52. Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL et al: Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS (1998) 12(18):2407-2415.
53. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (1990) 345(6276):622-625.
54. Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E et al: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 72(2):1552-1576.
55. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH: Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol (1995) 69(1):39-48.
56. Cohen J: Clinical research. A setback and an advance on the AIDS vaccine front. Science (2003) 300(5616):28-29.
57. Stamatatos L, Cheng-Mayer C: An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol (1998) 72(10):7840-7845.
58. Reitter JN, Means RE, Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nat Med (1998) 4(6):679-684.
59. Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L: Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol (2003) 77(4):2310-2320.
60. Brander C, Walker BD: T lymphocyte responses in HIV-1 infection: Implications for vaccine development. Curr Opin Immunol (1999) 11(4):451-459.
61. Sheppard HW, Ascher MS: The relationship between AIDS and immunologic tolerance. J Acquir Immune Defic Syndr (1992) 5(2):143-147.
62. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Hemdon JG, Wyatt LS, Candido MA et al: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 292(5514):69-74.
63. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K et al: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 290(5491):486-492.
64. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L et al: Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature (2002) 415(6869):331-335.
65. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, Borrow P, Saag MS, Shaw GM, Sekaly RP, Fauci AS: Major expansion of CD8+ T cells with a predominant V β usage during the primary immune response to HIV. Nature (1994) 370(6489):463-467.
66. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 337(18):1267-1274.
67. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A et al: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 279(5359):2103-2106.
68. Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, Louie L, Eron J, Sheppard H, Frelinger JA: Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses (1999) 15(13):1219-1228.
69. Propato A, Schiaffella E, Vicenzi E, Francavilla V, Baloni L, Paroli M, Finocchi L, Tanigaki N, Ghezzi S, Ferrara R, Chesnut R et al: Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum Immunol (2001) 62(6):561-576.
70. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, Kiama P, Rutherford J, Njagi E, Mwangi F, Rostron T, Ohyango J et al: New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett (2001) 79(1-2):3-13.
71. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG et al: Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 189(6):991-998.
72. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 283(5403):857-860.
73. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 68(7):4650-4655.
74. Levy JA, Mackewicz CE, Barker E: Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today (1996) 17(5):217-224.
75. Berzofsky JA, Ahlers JD, Belyakov IM: Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol (2001) 1(3):209-219.
76. Bertram EM, Dawicki W, Watts TH: Role of T cell costimulation in anti-viral immunity. Semin Immunol (2004) 16(3):185-196.
77. Dranoff G: CTLA-4 blockade: Unveiling immune regulation. J Clin Oncol (2004): doi: 10.1200/JCO.2005.09.923.
78. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 270(5243):1811-1815.
79. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, DeVico AL: Inhibition of HIV-1 infection by the β-chemokine MDC. Science (1997) 278(5338):695-698.
80. Baier M, Werner A, Bannert N, Metzner K, Kurth R: HIV suppression by interleukin-16. Nature (1995) 378(6557):563.
81. Johnson RP, Siliciano RF, McElrath MJ: Cellular immune responses to HIV-1. AIDS (1998) 12(Suppl A):S113-S120.
82. Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, Silvera P, Dennis M, Corcoran T, Stott J et al: Early suppression of SIV replication by CD8+ net-specific cytotoxic T cells in vaccinated macaques. Nat Med (1995) 1(11):1167-1173.
83. Kumar A, Mukherjee S, Shen J, Buch S, Li Z, Adany I, Liu Z, Zhuge W, Piatak M Jr, Lifson J, McClure H et al: Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Virology (2002) 301(2):189-205.
84. Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, VanCott TC, Hirsch V, Woodward R et al: ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 76(1):292-302.
85. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK: An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 106(5):539-549.
86. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR, McMichael AJ: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (1991) 354(6353):453-459.
87. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 3(2):205-211.
88. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M et al: Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 412(6844):334-338.
89. Evans DT, O'Connor DH, Jing P, Dzuris JL, Sidney J, da Silva J, Allen TM, Horton H, Venham JE, Rudersdorf RA, Vogel T et al: Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus env and nef. Nat Med (1999) 5(11):1270-1276.
90. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ et al: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 407(6802):386-390.
91. Chen ZW, Craiu A, Shen L, Kuroda MJ, Iroku UC, Watkins DI, Voss G, Letvin NL: Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J Immunol (2000) 164(12):6474-6479.
92. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyeri FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC et al: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 415(6869):335-339.
93. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ et al: Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 3(2):212-217.
94. McMichael A, Hanke T: The quest for an AIDS vaccine: Is the CD8+ T-cell approach feasible? Nat Rev Immunol (2002) 2(4):283-291.
95. Cotropia J, Ugen KE, Kliks S, Broliden K, Broliden PA, Hoxie JA, Srikantan V, Williams WV, Weiner DB: A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 12(3):221-232.
96. Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H, Stiegler G, Cavacini LA, Bai Y, Cotropia J, Ugen KE, Ruprecht RM: Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies - implications for acquired immunodeficiency syndrome vaccine. J Infect Dis (2004) 189(1):71-74.
97. Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, Zolla-Pazner S: Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies, Int Immunol (1997) 9(9):1281-1290.
98. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 75(22):10892-10905.
99. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 67(11):6642-6647.
100. Barbas CF 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, Burton DR: Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA (1992) 89(19):9339-9343.
101. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun NC, Robinson JE: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol (1991) 65(1):489-493.
102. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol (1993) 67(7):3978-3988.
103. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW et al: Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA (2002) 99(10):6913-6918.
104. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 70(2):1100-1108.
105. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 68(12):8312-8320.
106. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S: Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 66(12):7538-7542.
107. Scott CF Jr, Silver S, Profy AT, Putney SD, Langlois A, Weinhold K, Robinson JE: Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc Natl Acad Sci USA (1990) 87(21):8597-8601.